P38 mitogen-activated protein kinase is involved in arginase-II-mediated eNOS-Uncoupling in Obesity

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Yu, Yi ^a   Rajapakse, Angana G ^a   Montani, Jean Pierre ^a   Yang, Zhihong ^a   Ming, Xiu Fen ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Arginase II; eNOS uncoupling; Obesity; p38mapk

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4,5 DIAMINOFLUORESCEIN DIACETATE; ACETYLCHOLINE; ARGINASE; ARGINASE II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROETHIDINE; MITOGEN ACTIVATED PROTEIN KINASE P38; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; SUPEROXIDE; UNCLASSIFIED DRUG; ARG2 PROTEIN, MOUSE; ARGINASE II, HUMAN; ARGININE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIPID DIET; MOUSE; NONHUMAN; OBESITY; UMBILICAL VEIN ENDOTHELIAL CELL; VASOMOTOR REFLEX; WILD TYPE; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ARGINASE; ARGININE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84905963361     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0113-z     Document Type: Article

References (38)

1. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH, American Heart A. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898-918. 10.1161/CIRCULATIONAHA.106.171016, 16380542.
2. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97:2601-2610. 10.1172/JCI118709, 8647954.
3. Williams IL, Wheatcroft SB, Shah AM, Kearney MT. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord 2002, 26:754-764. 10.1038/sj.ijo.0801995, 12037644.
4. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23:233-246. 10.1097/00004872-200502000-00001, 15662207.
5. Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006, 4:53-65. 10.3121/cmr.4.1.53, 16595793.
6. Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab 2012, 302:E481-E495. 10.1152/ajpendo.00540.2011, 22167522.
7. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012, 33:829-837. 10.1093/eurheartj/ehr304, 21890489.
8. Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, Soucy KG, Santhanam L, Webb A, Camara A, Sikka G, Nyhan D, Shoukas AA, Ilies M, Christianson DW, Champion HC, Berkowitz DE. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol 2009, 107:1249-1257. 10.1152/japplphysiol.91393.2008, 19661445.
9. Yang Z, Ming XF. Arginase: the emerging therapeutic target for vascular oxidative stress and inflammation. Front Immunol 2013, 4:149. 10.3389/fimmu.2013.00149, 23781221.
10. Yepuri G, Velagapudi S, Xiong Y, Rajapakse AG, Montani JP, Ming XF, Yang Z. Positive crosstalk between arginase-II and S6K1 in vascular endothelial inflammation and aging. Aging Cell 2012, 11:1005-1016. 10.1111/acel.12001, 22928666.
11. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, Hayoz D, Ruffieux J, Rusconi S, Montani JP, Yang Z. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 2004, 110:3708-3714. 10.1161/01.CIR.0000142867.26182.32, 15569838.
12. Ming XF, Rajapakse AG, Yepuri G, Xiong Y, Carvas JM, Ruffieux J, Scerri I, Wu Z, Popp K, Li J, Sartori C, Scherrer U, Kwak BR, Montani JP, Yang Z. Arginase II Promotes Macrophage Inflammatory Responses Through Mitochondrial Reactive Oxygen Species, Contributing to Insulin Resistance and Atherogenesis. J Am Heart Assoc 2012, 1:e000992. 10.1161/JAHA.112.000992, 23130157.
13. Ketonen J, Pilvi T, Mervaala E. Caloric restriction reverses high-fat diet-induced endothelial dysfunction and vascular superoxide production in C57Bl/6 mice. Heart Vessels 2010, 25:254-262. 10.1007/s00380-009-1182-x, 20512454.
14. Martin ED, De Nicola GF, Marber MS. New therapeutic targets in cardiology p38 alpha mitogen-activated protein kinase for ischemic heart disease. Circulation 2012, 126:357-368. 10.1161/CIRCULATIONAHA.111.071886.
15. Wu Z, Xiong Y, Gajanayake T, Ming XF, Yang Z. p38 mitogen-activated protein kinase is required for glucosamine-induced endothelial nitric oxide synthase uncoupling and plasminogen-activator inhibitor expression. Circ J 2012, 76:2015-2022. 10.1253/circj.CJ-12-0016, 22572461.
16. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol R 2004, 68:320-344. 10.1128/MMBR.68.2.320-344.2004.
17. Seeger FH, Sedding D, Langheinrich AC, Haendeler J, Zeiher AM, Dimmeler S. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol 2010, 105:389-397. 10.1007/s00395-009-0072-9, 19911112.
18. Sun Y, Ishibashi M, Seimon T, Lee M, Sharma SM, Fitzgerald KA, Samokhin AO, Wang YB, Sayers S, Aikawa M, Jerome WG, Ostrowski MC, Bromme D, Libby P, Tabas IA, Welch CL, Tall AR. Free cholesterol accumulation in macrophage membranes activates toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res 2009, 104:455-465. 10.1161/CIRCRESAHA.108.182568, 19122179.
19. Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, Wang CL, Lee JC, Feuerstein GZ, Yue TL. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999, 99:1685-1691. 10.1161/01.CIR.99.13.1685, 10190877.
20. Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SM, Maki-Petaja KM, Collier DJ, Morgan J, Fang Z, Willette RN, Lepore JJ, Cockcroft JR, Sprecher DL, Wilkinson IB. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 2011, 123:515-523. 10.1161/CIRCULATIONAHA.110.971986, 21262998.
21. Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R, Willette RN, Jucker BM. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis - MRI assessment. Arterioscl Throm Vasc 2008, 28:265-271. 10.1161/ATVBAHA.107.151175.
22. Grethe S, Ares MPS, Andersson T, Porn-Ares MI. p38 MAPK mediates TNF-induced apoptosis in endothelial cells via phosphorylation and downregulation of Bcl-x(L). Exp Cell Res 2004, 298:632-642. 10.1016/j.yexcr.2004.05.007, 15265709.
23. Shan HY, Bai XJ, Chen XM. Angiotensin II induces endothelial cell senescence via the activation of mitogen-activated protein kinases. Cell Biochem Funct 2008, 26:459-466. 10.1002/cbf.1467, 18383564.
24. Vaziri ND, Xu ZG, Shahkarami A, Huang KT, Rodriguez-Iturbe B, Natarajan R. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. Kidney Int 2005, 68:2787-2793. 10.1111/j.1523-1755.2005.00750.x, 16316354.
25. Toque HA, Romero MJ, Tostes RC, Shatanawi A, Chandra S, Carneiro ZN, Inscho EW, Webb RC, Caldwell RB, Caldwell RW. p38 Mitogen-Activated Protein Kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II-treated mice. J Sex Med 2010, 7:3857-3867. 10.1111/j.1743-6109.2010.01996.x, 20807329.
26. Shi O, Morris SM, Zoghbi H, Porter CW, O'Brien WE. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol 2001, 21:811-813. 10.1128/MCB.21.3.811-813.2001, 11154268.
27. Rajapakse AG, Yepuri G, Carvas JM, Stein S, Matter CM, Scerri I, Ruffieux J, Montani JP, Ming XF, Yang Z. Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: inhibition by resveratrol. Plos One 2011, 6:e19237. 10.1371/journal.pone.0019237, 21544240.
28. Roberts AC, Porter KE. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res 2013, 10:472-482. 10.1177/1479164113500680, 24002671.
29. Rask-Madsen C, King GL. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007, 3:46-56. 10.1038/ncpendmet0366, 17179929.
30. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 2001, 276:30392-30398. 10.1074/jbc.M103702200, 11402048.
31. Yu QJ, Gao F, Ma XL. Insulin says NO to cardiovascular disease. Cardiovasc Res 2011, 89:516-524. 10.1093/cvr/cvq349, 21051417.
32. Bivalacqua TJ, Hellstrom WJG, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: In diabetic-associated erectile dysfunction. Biochem Bioph Res Co 2001, 283:923-927. 10.1006/bbrc.2001.4874.
33. Kim NN, Cox JD, Baggio RF, Emig FA, Mistry SK, Harper SL, Speicher DW, Morris SM, Ash DE, Traish A, Christianson DW. Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry 2001, 40:2678-2688. 10.1021/bi002317h, 11258879.
34. Touyz RM, He G, El Mabrouk M, Schiffrin EL. p38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension 2001, 37:574-580. 10.1161/01.HYP.37.2.574, 11230337.
35. Kim SW, Kim CE, Kim MH. Flavonoids inhibit high glucose-induced up-regulation of ICAM-1 via the p38 MAPK pathway in human vein endothelial cells. Biochem Biophys Res Commun 2011, 415:602-607. 10.1016/j.bbrc.2011.10.115, 22074828.
36. Lu H, Yao K, Huang D, Sun A, Zou Y, Qian J, Ge J. High glucose induces upregulation of scavenger receptors and promotes maturation of dendritic cells. Cardiovasc Diabetol 2013, 12:80. 10.1186/1475-2840-12-80, 23718574.
37. Xu W, Wu W, Chen J, Guo R, Lin J, Liao X, Feng J. Exogenous hydrogen sulfide protects H9c2 cardiac cells against high glucose-induced injury by inhibiting the activities of the p38 MAPK and ERK1/2 pathways. Int J Mol Med 2013, 32:917-925. 23912965.
38. Zhu M, Chen J, Jiang H, Miao C. Propofol protects against high glucose-induced endothelial adhesion molecules expression in human umbilical vein endothelial cells. Cardiovasc Diabetol 2013, 12:13. 10.1186/1475-2840-12-13, 23311470.